Behind the continuous exodus of AstraZeneca Chinese executives...
Wen 丨 Bu Yuan
Today, it was announced that according to AstraZeneca China's internal email, Mr. Zhu Tong, Vice President of AstraZeneca China and head of the Cardiovascular, Kidney and Metabolism Business Unit, decided to leave AstraZeneca China to seek career development opportunities externally.
Zhu Tong Image source - public number: ProHR Huihua
It is reported that Zhu Tong's term of office will officially end on April 9, 2022. From now on, AstraZeneca China's Cardiovascular, Kidney and Metabolism Division, which Zhu Tong is responsible for, will be temporarily led by Lai Minglong, General Manager of AstraZeneca China.
The following is Zhu Tong's main resume:
- In 2001, Zhu Tong graduated from Zhejiang University. Since then, he has worked in Roche, Novartis and BMS, involving sales and marketing departments.
- In 2015, Tong Zhu joined AstraZeneca China as The Marketing Director of Keding ®.
- In 2017, Zhu Tong joined Sanofi as the head of the business unit.
- In 2019, Zhu Tong returned to AstraZeneca China as assistant president and head of cardiovascular treatment.
- In 2021, Zhu Tong was promoted to Vice President of AstraZeneca China.
- In November 2021, AstraZeneca China Cardiovascular & Metabolic Division and Kidney Business Unit were merged into: Cardiovascular, Renal & Metabolic Division. Zhu Tong was appointed head of the combined Cardiovascular, Renal and Metabolic Business Units.
In Zhu Tong's departure notice, AstraZeneca China highly affirmed zhu Tong's promotion work and achievements in belinda, kodine ® ®, blood lipid Kang capsules, AndaTang ® and other products that Zhu Tong was responsible for in AstraZeneca China since 2019. At the same time, his management ability and talent development and training methods were also praised.
Nine executives left in a row in 10 months
Zhu Tong's departure means that AstraZeneca China has left its executives again...
According to statistics, since July 2021, AstraZeneca China has had 9 senior executives left, becoming the multinational pharmaceutical company with the most frequent executive changes in the past year.
(1) In July 2021, Dong Lijun, general manager of AstraZeneca China's Digestion and Full Product Development Business Unit, announced her resignation and subsequently joined Luoxin Pharmaceutical as deputy general manager, executive vice president and chief operating officer (COO).
(2) In August 2021, Jing Xu, Vice President of AstraZeneca China and Head of Digital and Business Innovation, announced her resignation in order to seek external career opportunities.
(3) In September 2021, Zhang Anwei, chairman of the sales advisory committee of AstraZeneca's former Eastern RGM, left his post. Subsequently, Zhang Anwei joined Luoxin Group as the general manager of sales and vice president of the group of innovative drugs direct business.
(4) In October 2021, AstraZeneca China Digestion and Respiratory Atomization Business Unit (GNR) Assistant Vice President He Yimin left AstraZeneca. Subsequently, He Yimin joined Roche Pharmaceutical as the head of the field of gastrointestinal tumor treatment.
(5) In November 2021, AstraZeneca China Vice President and Head of County Business Unit Du Haochen resigned. Subsequently, Du Haochen joined BeiGene as the head of the broad market.
(6) In December 2021, Wang Dong, vice president and head of the retail business unit of AstraZeneca China, announced his resignation.
(7) In December 2021, Yin Min, general manager of AstraZeneca China Cancer Division, left his job. Yin Min then joined BeiGene as Chief Commercial Officer for Greater China.
(8) In February 2022, AstraZeneca and the head of the county team He Shuzhen left.
(9) In March 2022, Zhu Tong left his post.
Frequently adjusted business units
Behind the continuous exodus of AstraZeneca's Chinese executives is first of all closely related to its frequently adjusted business units.
In 2021, AstraZeneca China's multiple business units will be split and merged:
- Digestion and respiratory atomization businesses were merged to form the Digestion and Respiratory Atomization Business Unit (GNR);
- The Cardiovascular and Metabolic Division and the Kidney Business Department were merged to form the Cardiovascular, Renal and Metabolic Division;
- And the county business was split, and the county cancer business was merged into the oncology business department, and the county non-tumor business was established separately as the county chronic disease business department;
- In addition, AstraZeneca has established a rare disease business unit...
Year 2022:
In January, AstraZeneca China officially established the Omnichannel Business Unit, covering the county chronic disease business department, retail business department, community business department, Flying Eagle business department and the five county markets in the east.
It is reported that AstraZeneca China Omnichannel Business Unit refers to markets and channels other than the core market, aiming to increase the synergy and productivity of multiple channels, and strengthen the stickiness and collaboration between various disease areas, product portfolios and commercial channels.
In February, AstraZeneca China formally merged R&I (Respiratory and Autoimmune Division) and GNR (Digestion and Respiratory Atomization Division) to establish RGI (Respiratory, Digestive and Autoimmune Division).
It is reported that after the adjustment, AstraZeneca China's latest business structure is divided into the following four sectors:
1. Cancer Division;
2. Respiratory, Digestive and Autoimmune Division;
3. Cardiovascular, Renal and Metabolic Division;
4. Rare Disease Division.
In addition, behind the continuous departure of AstraZeneca's Chinese executives, there may also be a certain relationship with its performance in China.
On February 10, 2022, AstraZeneca announced its fiscal 2021 annual report, and the China business fell by 4% year-on-year in the fourth quarter, the first decline in five years.
According to the financial report, AstraZeneca China's full-year revenue fell to $1.312 billion from $1.362 billion in the same period of fiscal 2020, and its share of global revenue fell from 20% in 2020 to 16%.
It is worth mentioning that at a time when AstraZeneca's performance is under pressure and personnel turmoil, in 2022, AstraZeneca China also broke out a "employee fraud insurance" scandal, which once again plunged AstraZeneca into "deep water".
Who are the latest business unit leaders?
Image source: AstraZeneca China official website
In January 2022, AstraZeneca China appointed Qian Liu, Vice President of AstraZeneca China, as head of the Omnichannel Business Unit.
In January 2022, AstraZeneca China appointed Lili Zhu as Vice President of AstraZeneca China, Head of Digital & Business Innovation, Business Strategy & Operations Excellence. It is reported that Zhu Lili was the head of Pfizer's Global Business Operations Department (GCO) China, Huizhi China Innovation and Digital Health Business Unit and Greater China Business Operation Efficiency Business Unit.
In February 2022, after AstraZeneca China established RGI (Respiratory, Digestive and Autoimmune Division), Lin Xiao, Vice President of AstraZeneca China and former head of The Respiratory and Autoimmune Business Unit, was responsible for leading the new business unit.
In March 2022, Chen Kangwei, former General Manager of AstraZeneca's Taiwan region, took over Yin Min's previous position as General Manager of AstraZeneca's China Oncology Division, and was fully responsible for AstraZeneca's Oncology business in China.
furthermore:
AstraZeneca China's Oncology Urology, Gynecology and Women's Oncology Division is now led by Qiong Xie, Vice President of AstraZeneca China.
AstraZeneca China's Targeted Lung Cancer Therapy and Tumor Immunotherapy Related Business Unit is now led by Zhu Jiakang, Vice President of AstraZeneca China.
References: E Medicine Dog Zi "AstraZeneca Zhu Tong's Departure.....